• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

    2/19/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care
    Get the next $LUNG alert in real time by email

    REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.

    Recent Highlights

    • Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior year
    • Achieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basis
    • Set a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 2024, representing 16% and 23% year-over-year growth, respectively
    • Realized gross margin of 74% in the fourth quarter of 2024 and 74% for the full year of 2024
    • Added 11 new Zephyr® Valve U.S. treatment centers in the fourth quarter of 2024
    • Partnered with American Lung Association to launch new educational initiatives for COPD patients and providers
    • Implemented LungTraX™ software platform in first U.S. pilot sites

    "Our record quarterly and full year results underscore the continued success of our focused strategy and execution in further expanding our account base, optimizing patient workflows, and raising awareness among both patients and referring physicians," said Steve Williamson, President & Chief Executive Officer. "With strong underlying demand and ongoing momentum, particularly with the pilot launch of the LungTraX software platform, we are confident in our ability to drive long-term, sustainable growth in 2025 and beyond."

    Fourth Quarter 2024 Financial Results

    Total worldwide revenue in the fourth quarter of 2024 was $23.8 million, a 23% increase from $19.3 million in the fourth quarter of 2023 and an increase of 23% on a constant currency basis. U.S. revenue was $15.9 million, a 16% increase from the fourth quarter of 2023. International revenue was $7.9 million, a 42% increase compared to the fourth quarter of 2023, and a 40% increase on a constant currency basis.

    Gross profit in the fourth quarter of 2024 was $17.6 million, compared to $14.4 million for the fourth quarter of 2023. Gross margin for the fourth quarter of 2024 was 74%, compared to 75% for the same period in 2023.

    Operating expenses in the fourth quarter of 2024 were $31.0 million, compared to $28.3 million for the fourth quarter of 2023, representing an increase of 9%. The increase in operating expenses was primarily attributable to continued investments in our commercial activities and higher clinical expenses.

    Net loss in the fourth quarter of 2024 was $13.2 million, or $0.33 per share, compared to a net loss of $13.9 million, or $0.36 per share, for the same period in 2023.

    Adjusted EBITDA loss in the fourth quarter of 2024 was $7.5 million compared to $8.4 million for the same period in 2023.

    Full Year 2024 Financial Results

    Total worldwide revenue for the full year of 2024 was $83.8 million, a 22% increase from $68.7 million for the full year of 2023 and an increase of 22% on a constant currency basis. U.S. revenue was $56.5 million, a 23% increase from $45.9 million for the full year of 2023. International revenue was $27.3 million, a 20% increase from $22.8 million for the full year of 2023, and a 19% increase on a constant currency basis. The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures.

    Gross profit for the full year of 2024 was $62.0 million, a 22% increase compared to $50.8 million for the full year of 2023. Gross margin for the full year of 2024 was 74%, approximately in line with the prior year.

    Operating expenses for the full year of 2024 were $119.7 million, compared to $112.7 million for the full year of 2023, representing an increase of 6%. The increase in operating expenses was primarily attributable to continued investments in our commercial activities and clinical development costs related to our AeriSeal program.

    Net loss for the full year of 2024 was $56.4 million, or $1.44 per share, compared to a net loss of $60.8 million, or $1.60 per share, for the same period in 2023.

    Adjusted EBITDA loss for the full year of 2024 was $31.3 million compared to $39.0 million for the full year of 2023.

    Cash, cash equivalents, and marketable securities totaled $101.5 million as of December 31, 2024.

    Full Year 2025 Financial Guidance

    Pulmonx expects revenue for the full year 2025 to be in the range of $96 million to $98 million, representing growth of 15% to 17% compared to 2024, or 16% to 18% on a constant currency basis, as our guidance assumes a negative impact from foreign exchange on reported revenue growth of approximately 100 basis points.

    The Company expects gross margin for the full year 2025 to be approximately 74%.

    Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation.

    Webcast and Conference Call Details

    Pulmonx will host a conference call today, February 19, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2024 financial results and to discuss its full year 2025 financial guidance. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

    Use of Non-GAAP Financial Measures

    To supplement Pulmonx's condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx's business.

    Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors' ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx's historical operating results.

    The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.

    Reconciliation of non-GAAP financial measures to the most comparable GAAP measures for the fourth quarter and full year ended December 31, 2024 and 2023 is set forth in the tables below.

    The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our strategy and execution in further optimizing patient workflows, and raising awareness among both patients and referring physicians, our expectations regarding demand and ongoing momentum, including with respect to the pilot launch of the LungTraX software platform, our ability to drive long-term, sustainable growth in 2025 and beyond, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, guidance for full year 2025, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of our filings with the Securities and Exchange Commission ("SEC"), including our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 1, 2024, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

    About Pulmonx Corporation

    Pulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. 

    Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.  

    Investor Contact

    Brian Johnston

    Laine Morgan

    Gilmartin Group

    [email protected]

     
    Pulmonx Corporation

    Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (Unaudited)
         
      Three Months Ended December 31, Twelve Months Ended December 31,
      2024 2023 2024 2023
    Revenue $23,765  $19,278  $83,789  $68,675 
    Cost of goods sold  6,175   4,878   21,788   17,923 
    Gross profit  17,590   14,400   62,001   50,752 
    Operating expenses        
    Research and development  4,001   3,896   17,570   18,080 
    Selling, general and administrative  27,006   24,423   102,135   94,607 
    Total operating expenses  31,007   28,319   119,705   112,687 
    Loss from operations  (13,417)  (13,919)  (57,704)  (61,935)
    Interest income  1,045   1,541   5,061   5,568 
    Interest expense  (842)  (905)  (3,507)  (3,232)
    Other income (expense), net  77   (357)  256   (673)
    Net loss before tax  (13,137)  (13,640)  (55,894)  (60,272)
    Income tax expense  38   248   500   571 
    Net loss $(13,175) $(13,888) $(56,394) $(60,843)
    Net loss per share attributable to common stockholders, basic and diluted $(0.33) $(0.36) $(1.44) $(1.60)
    Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted  39,581,760   38,377,404   39,111,073   37,974,567 
                     



     
    Pulmonx Corporation

    Condensed Consolidated Balance Sheets

    (in thousands)

    (Unaudited)
        
     December 31, 2024 December 31, 2023
    Assets   
    Current assets   
    Cash and cash equivalents$70,905  $83,547 
    Restricted cash 257   237 
    Short-term marketable securities 30,577   33,555 
    Accounts receivable, net 13,120   12,105 
    Inventory 16,915   16,743 
    Prepaid expenses and other current assets 4,474   4,235 
    Total current assets 136,248   150,422 
    Long-term marketable securities —   14,390 
    Long-term inventory 1,681   2,580 
    Property and equipment, net 2,907   4,028 
    Goodwill 2,333   2,333 
    Intangible assets, net —   31 
    Right of use assets 18,545   3,406 
    Other long-term assets 1,136   591 
    Total assets$162,850  $177,781 
        
    Liabilities and Stockholders' Equity   
    Current liabilities   
    Accounts payable$3,827  $1,497 
    Accrued liabilities 16,472   16,234 
    Income taxes payable 49   93 
    Deferred revenue 135   104 
    Short-term debt 3,176   2,155 
    Current lease liabilities 778   3,074 
    Total current liabilities 24,437   23,157 
    Deferred tax liability 87   114 
    Long-term lease liabilities 18,515   1,106 
    Long-term debt 34,002   35,089 
    Total liabilities 77,041   59,466 
    Stockholders' equity   
    Common stock 40   39 
    Additional paid-in capital 551,211   526,797 
    Accumulated other comprehensive income 2,113   2,640 
    Accumulated deficit (467,555)  (411,161)
    Total stockholders' equity 85,809   118,315 
    Total liabilities and stockholders' equity$162,850  $177,781 
            



     
    Pulmonx Corporation

    Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change

    (in thousands)

    (Unaudited)
            
     Three Months Ended December 31,      
     2024

     2023

     % Change FX Impact % Constant Currency % Change
    United States$15,879  $13,720  15.7% —% 15.7%
    International 7,886   5,558  41.9% 2.2% 39.7%
    Total$23,765  $19,278  23.3% 0.7% 22.6%



     Twelve Months Ended December 31,      
     2024

     2023

     % Change FX Impact % Constant Currency % Change
    United States$56,465  $45,917  23.0% —% 23.0%
    International 27,324   22,758  20.1% 1.2% 18.9%
    Total$83,789  $68,675  22.0% 0.4% 21.6%
              



     
    Pulmonx Corporation

    Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA

    (in thousands)

    (Unaudited)
        
     Three Months Ended December 31, Twelve Months Ended December 31,
     2024 2023 2024 2023
    GAAP Net loss$(13,175) $(13,888) $(56,394) $(60,843)
    Depreciation and amortization 294   287   1,493   1,548 
    Stock-based compensation 5,523   5,598   22,955   22,101 
    Impairment of capitalized software development costs —   —   1,717   — 
    Interest (income)/expense, net (203)  (636)  (1,554)  (2,336)
    Provision for income taxes 38   248   500   571 
    Adjusted EBITDA$(7,523) $(8,391) $(31,283) $(38,959)
                    


    Primary Logo

    Get the next $LUNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNG

    DatePrice TargetRatingAnalyst
    3/10/2025$17.00Buy
    D. Boral Capital
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    6/4/2024$12.00Buy
    Lake Street
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    9/5/2023$18.00Buy
    Craig Hallum
    2/27/2023$10.00 → $15.00Equal Weight → Overweight
    Wells Fargo
    1/3/2023$8.00Neutral → Underperform
    BofA Securities
    12/12/2022$14.00 → $10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va

      5/1/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

      REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

      4/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/14/24 7:47:49 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/12/24 10:34:16 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/8/24 10:35:45 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

      REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

      4/2/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

      REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

      2/21/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

      LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

      12/11/23 9:00:00 AM ET
      $HNST
      $LUNG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care

    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Pulmonx with a new price target

      D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

      3/10/25 8:07:21 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx downgraded by Citigroup with a new price target

      Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

      12/11/24 7:54:19 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Pulmonx with a new price target

      Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00

      6/4/24 8:21:23 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      8/22/24 6:41:17 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director French Glendon E. Iii sold $157,000 worth of shares (20,000 units at $7.85), decreasing direct ownership by 2% to 991,974 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/21/25 6:14:28 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer & PAO Joshi Mehul sold $102,414 worth of shares (14,384 units at $7.12) and was granted 108,000 shares, increasing direct ownership by 73% to 221,986 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:12:01 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND CEO Williamson Steven S. sold $197,699 worth of shares (27,689 units at $7.14) and was granted 181,696 shares, increasing direct ownership by 69% to 376,038 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:09:24 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Financials

    Live finance-specific insights

    See more
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

      REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

      4/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

      REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

      2/19/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

      SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

      5/7/25 11:47:10 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Pulmonx Corporation

      10-Q - Pulmonx Corp (0001127537) (Filer)

      5/2/25 4:18:52 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pulmonx Corp (0001127537) (Filer)

      4/30/25 4:10:52 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care